HbA1c and beyond.

Area of Science:

• Nephrology
• Endocrinology
• Clinical Practice Guidelines

Background:

• The 2020 KDIGO guideline addresses the complex management of patients with both diabetes and chronic kidney disease (CKD).
• This population faces high risks of adverse health outcomes.
• Recent advancements in diabetes technology and therapeutics provide new management options.

Purpose of the Study:

• To optimize clinical care for individuals with diabetes and CKD.
• To integrate novel therapeutic options with existing management strategies.
• To provide evidence-based recommendations for comprehensive patient care.

Main Methods:

• Review of high-quality evidence, focusing on recent clinical trials.
• Analysis of new developments in diabetes management since the guideline's publication.
• Emphasis on comprehensive care, glycaemic monitoring, targets, and antihyperglycaemic therapies.

Main Results:

• Emerging evidence supports organ-protective treatments beyond glucose control, including SGLT2 inhibitors and GLP-1 receptor agonists.
• These new interventions offer expanded therapeutic opportunities for patients with diabetes and CKD.
• The guideline aims to integrate these advancements into current clinical practice.

Conclusions:

• The 2020 KDIGO guideline provides a framework for managing diabetes in CKD patients using the latest evidence.
• New therapeutic classes offer significant benefits for organ protection and overall patient outcomes.
• Optimized management strategies are crucial for this high-risk population.